NAGE Stock — Niagen Bioscience, Inc.

Niagen Bioscience, Inc. (NAGE)

Updated October 16, 2026.

NAGE is a Stock. Total return is -78.7% over the past 18.3 years, 785.7 points behind SPY at 707.0%.

Niagen Bioscience, Inc. is a bioscience company developing healthy aging products across three business segments: consumer dietary supplements containing proprietary ingredients sold direct-to-consumer and through retailers; ingredient manufacturing and supply of nicotinamide riboside (marketed as Niagen) and other NAD+ precursors to consumer product manufacturers; and pharmaceutical development of proprietary ingredient technologies. The company does not currently have an established distribution schedule. This security may appeal to investors interested in the healthy aging and nutritional supplement sectors.

NAGE performance versus SPY

Price and return data through 2026-10-16.

Total return is -78.7% over the past 18.3 years, 785.7 points behind SPY at 707.0%. Over the past year its total return — price change plus distributions reinvested — is -66.4%. Its deepest 1-year drawdown was 67.2%.

NAGE key facts

Asset type

Stock

Asset class

Equity

Inception date

06/25/2008

Distribution frequency

None

Last close

$2.49 (as of 2026-10-16)

Market cap

$198,314,374

Average volume

555766.0

Beta

2.017

Payout ratio

0.0%

P/E ratio

13.11

Forward P/E

21.5054

EPS

$0.19

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NAGE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 67.2%.

Who may consider NAGE — and who may not

It is a weaker fit for investors who need monthly cash flow (NAGE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NAGE

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions